The table below shows Spyre Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$57.37M
-$40.99M
-$28.54M
-$17.63M
-$26.26M
-$19.53M
Capital expenditure
-
-
-
-
$37.00K
$450.00K
Investing cash flow
$56.58M
-$61.00K
-$104.96M
$17.75M
$25.76M
$9.30M
Dividends paid
-
-
-
-
SYRE operating cash flow (10-K history)
Spyre Therapeutics, Inc. reported operating cash flow of -$169.25M for fiscal year 2025. That is down 7.5% from -$157.41M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$18.84M (FY 2016) to -$169.25M. Figures come from the company's audited annual reports as filed with the SEC.